Brief: Hungary's Richter says it voluntarily restricts price of its non-prescription product Panangin
11/06/2025 07:13
June 11 (Reuters) - Richter Gedeon Vegyeszeti Gyar Nyrt GDRB.BU says in a statement: IT AGREES TO VOLUNTARY PRICE RESTRICTION HUNGARY'S RICHTER SAYS IT UNDERSTANDS AND SUPPORTS THE HUNGARIAN GOVERNMENT'S EFFORTS TO REDUCE THE BURDEN ON PATIENTS HUNGARY'S RICHTER SAYS IT VOLUNTARILY RESTRICTS PRICE OF ITS NON-PRESCRIPTION PRODUCT PANANGIN FROM JUNE 16 PANANGIN IS A MAGNESIUM AND POTASSIUM DIETARY SUPPLEMENT AND COMPLEMENTARY TREATMENT FOR CHRONIC HEART DISEASE AND CARDIAC ARRHYTMIAS PRICE OF THE PRODUCT WILL BE REDUCED TO THE LEVEL THAT WAS IN PLACE ON 31 DECEMBER 2024 ANNUAL IMPACT OF THE PRICE RESTRICTION IS ESTIMATED TO BE AROUND HUF 100 MILLION Source text: [https://www.bse.hu/newkibdata/129272931/Drugprice_June2025_EN.pdf] Further company coverage: GDRB.BU (Reporting by Anita Komuves) ((KOMUVES.Anita@thomsonreuters.com;))
Recent news on Richter Gedeon Vegyeszeti Gyar Nyrt
See all newsAI in Hungary could unlock productivity gains of €15 billion, McKinsey says
Brief: Hungary's Richter and Hetero announce cooperation for development of semaglutide injection
Brief: Hungary's Richter and Acrux agree to license transdermal Estradiol spray for Australia
Brief: Hungary's Richter Says 2026 Guidance Fully Reiterated High-Single-Digit Growth In Revenues And Clean EBIT (At Constant Exchange Rates)
Brief: Hungary's Richter says European Commission granted approval for Tuyory, its biosimilar to Tocilizumab